Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 16/20 | 0.74 |
| ▸ | CCKBR | P32239 | 1/20 | 0.64 |
| ▸ | GLP1R | P43220 | 1/20 | 0.64 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.64 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teriparatide SCHEMBL29354459 | 0.90 | PTH1R (0.91) | PTH1RCCKBRGLP1R | |
| SCHEMBL28980015 | 0.90 | PTH1R (0.91) | PTH1RCCKBRGLP1R | |
| SCHEMBL1773403 | 0.90 | PTH1R (0.85) | PTH1RCCKBRGLP1R | |
| SCHEMBL29738331 | 0.90 | PTH1R (0.68) | PTH1RCCKBRGLP1R | |
| Teriparatide SCHEMBL720581 | 0.89 | PTH1R (0.90) | PTH1RCCKBRGLP1R | |
| SCHEMBL29407563 | 0.89 | PTH1R (0.69) | PTH1R | |
| SCHEMBL29531990 | 0.89 | PTH1R (0.77) | PTH1RCCKBRGLP1RVIPR1VIPR2 | |
| Clavanin B SCHEMBL29549855 | 0.88 | PTH1R (0.66) | PTH1RGLP1RVIPR1VIPR2 | |
| SCHEMBL29732699 | 0.88 | PTH1R (0.72) | PTH1RCCKBRGLP1RVIPR1 | |
| SCHEMBL31295735 | 0.88 | PTH1R (0.58) | PTH1RCCKBRGLP1RVIPR1VIPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115332-A1 | Fibroblast Activation Protein Alpha-Cleavable Pro-Peptides and Methods of Use | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260116983-A1 | Anti-Urokinase-Type Plasminogen Activator Receptor Antibodies and Methods of Use | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | disclosed |
| US-12606937-B2 | Humanized antibodies with ultralong complementary determining regions | TAURUS BIOSCIENCES, LLC (US) | 2026-04-21 | — | — | US | disclosed |
| US-12545668-B2 | Cyclic amine derivative as agent for promoting advillin function, and novel cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. (JP) | 2026-02-10 | — | — | US | disclosed |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | NOVARTIS AG (CH) | 2025-10-07 | — | — | US | disclosed |
| US-20250281535-A1 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | ABOLERIS PHARMA (FR) | 2025-09-11 | — | — | US | disclosed |
| EP-4401842-B1 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | ABOLERIS PHARMA (FR) | 2025-08-27 | — | — | EP | disclosed |
| EP-4598574-A1 | ANTI-UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR ANTIBODIES AND METHODS OF USE | Shangpharma Innovation, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4596720-A2 | BACTERIAL LEADER SEQUENCES FOR PERIPLASMIC PROTEIN EXPRESSION | Pelican Technology Holdings, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4577554-A2 | FIBROBLAST ACTIVATION PROTEIN ALPHA-CLEAVABLE PRO-PEPTIDES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4028417-A1 | ANTI-ONCOLYTIC VIRUS ANTIGEN ANTIBODIES AND METHODS OF USING SAME | Admare Therapeutics Society (CA) | 2022-07-20 | — | — | EP | disclosed |
| EP-4028044-A1 | METHODS OF TREATING KRAS MUTANT CANCERS | The Board of Trustees of the Leland Stanford Junior University (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220213171-A1 | Ciliary Neurotrophic Factor Receptor Ligand-Binding Agents and Methods of Using the Same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-07-07 | — | — | US | disclosed |
| US-20220211861-A1 | DRUG CONJUGATES AND METHODS OF USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-07 | — | — | US | disclosed |
| US-20220202933-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220145175-A1 | Near-Infrared-II Nanoparticles and Related Compositions and Methods | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-05-12 | — | — | US | disclosed |
| EP-3972647-A1 | DRUG CONJUGATES AND METHODS OF USING SAME | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20220081431-A1 | CYCLIC AMINE DERIVATIVE AS AGENT FOR PROMOTING ADVILLIN FUNCTION, AND NOVEL CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2022-03-17 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606937-B2 | Humanized antibodies with ultralong complementary determining regions | IGLV6-57, FCGR3B, VSIR | PTH1R 659/4885CCKBR 1037/4885GLP1R 1251/4885 |
| US-12545668-B2 | Cyclic amine derivative as agent for promoting advillin function, and novel cyclic amine derivative and pharmaceutical use thereof | SSB, TLR9, C5AR2 | PTH1R 4883/4885CCKBR 4142/4885GLP1R 4791/4885 |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | PTH1R 4301/4885CCKBR 1601/4885GLP1R 2772/4885 |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | ABCB11, ABCB1, GHRHR | PTH1R 730/4885CCKBR 1374/4885GLP1R 843/4885 |
| US-20260116983-A1 | Anti-Urokinase-Type Plasminogen Activator Receptor Antibodies and Methods of Use | VSIG8, PLAUR, IGSF11 | PTH1R 1586/4885CCKBR 3925/4885GLP1R 2722/4885 |
| US-20260115332-A1 | Fibroblast Activation Protein Alpha-Cleavable Pro-Peptides and Methods of Use | FAP, FIBP, CTSL | PTH1R 881/4885CCKBR 2355/4885GLP1R 612/4885 |
| US-20220081431-A1 | CYCLIC AMINE DERIVATIVE AS AGENT FOR PROMOTING ADVILLIN FUNCTION, AND NOVEL CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | ADCY10, ADCK5, AANAT | PTH1R 4784/4885CCKBR 2598/4885GLP1R 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.